Serum neutralizing antibody develops following the majority of rhinovirus illnesses, which is important in preventing symptomatic infection.
Answers are grounded in this paper and cite their sources.
Antibody development after most rhinovirus cases supports immunity studies; leaves open vaccine correlates and duration of protection.
Rhinovirus illness in young adults was characterized by rhinorrhea, nasal obstruction, sneezing, and pharyngeal discomfort. Length of illness ranged from 1 to 33 days, with a median of 7.42 days; one fourth of the illnesses lasted two weeks. Nasal symptoms, hoarseness, and cough occurred more frequently with confirmed rhinovirus common colds than with illnesses from which rhinoviruses were not cultured. Significant neutralizing antibody responses were measured in 77% of 77 paired serum specimens from patients with rhinovirus illness; only 5% had homologous titers of 8 or more in the acute phase of illness. The findings support other data indicating that serum neutralizing antibody develops following the majority of rhinovirus illnesses and is important in preventing symptomatic rhinovirus infection.
No takes yet. Share an insight, caveat, or question.
Jack M. Gwaltney (1967) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: